Zhitong Finance App News, China Resources Shuanghe (600062.SH) issued an announcement. Recently, Beijing Shuanghe Runchuang Technology Co., Ltd., a wholly-owned subsidiary of the company, received the DC7001A capsule “Drug Clinical Trial Approval Notice” issued by the State Drug Administration. This drug is intended to treat systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.